Paper42549219
JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration.
Liu X and 1 other. Front Immunol, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration. Papers, record 42549219. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42549219
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- JAK1-preferential inhibition in refractory inflammatory bowel disease: reframing upadacitinib as a strategy for rapid immune recalibration.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Janus Kinase 1 | Major topic |
| Inflammatory Bowel Diseases | Major topic |
| Heterocyclic Compounds, 3-Ring | Major topic |
| Janus Kinase Inhibitors | Major topic |
| Humans | |
| Animals | |
| Signal Transduction | |
| Cytokines |
Source PubMed
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37423233 | Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. | Lancet Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/37423233 | PubMed |
| 2 | 35907636 | Efficacy of biological therapies and small molecules in induction and maintenance of remission in luminal Crohn's disease: systematic review and network meta-analysis. | Gut | 2023 | https://conductscience.org/library/papers/35907636 | PubMed |
| 3 | 29096949 | Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. | Lancet | 2017 | https://conductscience.org/library/papers/29096949 | PubMed |
| 4 | 36913180 | Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases. | Drugs | 2023 | https://conductscience.org/library/papers/36913180 | PubMed |
| 5 | 35397241 | Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. | Lancet Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/35397241 | PubMed |
| 6 | 39147217 | Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. | Clin Gastroenterol Hepatol | 2025 | https://conductscience.org/library/papers/39147217 | PubMed |
| 7 | 37224198 | Upadacitinib Induction and Maintenance Therapy for Crohn's Disease. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37224198 | PubMed |
| 8 | 38492903 | Upadacitinib Reduces Crohn's Disease Symptoms Within the First Week of Induction Therapy. | Clin Gastroenterol Hepatol | 2024 | https://conductscience.org/library/papers/38492903 | PubMed |
| 9 | 29104284 | JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. | Nat Rev Drug Discov | 2017 | https://conductscience.org/library/papers/29104284 | PubMed |
| 10 | 36807832 | Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature. | Dig Dis Sci | 2023 | https://conductscience.org/library/papers/36807832 | PubMed |
| 11 | 34876680 | Revisiting fibrosis in inflammatory bowel disease: the gut thickens. | Nat Rev Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/34876680 | PubMed |
| 12 | 35081280 | Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35081280 | PubMed |
| 13 | 35644166 | Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. | Lancet | 2022 | https://conductscience.org/library/papers/35644166 | PubMed |
| 14 | 36720660 | IBD disease-modifying therapies: insights from emerging therapeutics. | Trends Mol Med | 2023 | https://conductscience.org/library/papers/36720660 | PubMed |
| 15 | 39425738 | Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. | Gastroenterology | 2024 | https://conductscience.org/library/papers/39425738 | PubMed |
| 16 | 40741688 | ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1. | J Crohns Colitis | 2025 | https://conductscience.org/library/papers/40741688 | PubMed |
| 17 | 39572132 | AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. | Gastroenterology | 2024 | https://conductscience.org/library/papers/39572132 | PubMed |
| 18 | 37923366 | Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story. | Ann Rheum Dis | 2024 | https://conductscience.org/library/papers/37923366 | PubMed |
| 19 | 37932270 | Microbiome and metabolome features in inflammatory bowel disease via multi-omics integration analyses across cohorts. | Nat Commun | 2023 | https://conductscience.org/library/papers/37932270 | PubMed |
| 20 | 37231248 | Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. | Nat Rev Rheumatol | 2023 | https://conductscience.org/library/papers/37231248 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| JAK1 | 3716 | PubTator's text mining | https://conductscience.org/library/genes/3716 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42549219
GET https://conductscience.org/api/papers/v1/42549219/references?page=2